Posts

Posted on

Cinedigm Announces MyTime Movie Network, a New Female-Focused Linear Streaming Channel, Debuting Today on The Roku Channel

Cinedigm Announces MyTime Movie Network, a New Female-Focused Linear Streaming Channel, Debuting Today on The Roku Channel

MyTime Movie Network Is the First Female Focused Streaming Film Network Featuring Hundreds of Award-Winning Films, Original Series, Exclusive Content, & More

LOS ANGELES–(BUSINESS WIRE)–Cinedigm (NASDAQ: CIDM) announced today the launch of the all-new female-focused streaming linear channel MyTime Movie Network on The Roku Channel, the home of free and premium entertainment on the Roku® platform.

MyTime Movie Network offers an unparalleled library of curated content catering to women of all ages. The diverse library, which has been seen by a combined audience of upwards of 20 million viewers, features hundreds of popular and award-winning films. Upon its launch films from all genres will be available; ranging from pulse-pounding thrillers such as Final Girl, starring Abigail Breslin; and charming date-night comedies such as What Goes Up, starring Hilary Duff; to feel-good musicals such as Pure Country 2 starring Michael McKean; family dramas such as The Reliant, starring Kevin Sorbo; and everything in-between.

In addition to its library of films, the network delivers a fresh slate of over 50 original films that will be exclusively available on MyTime Movie Network.

“We are excited to bring MyTime to The Roku Channel,” said Alexandra Viglione, Head of Product for Cinedigm Digital Networks. “Quality programming directly targeting the female viewer is important and we know MyTime will deliver entertaining and diverse content to that audience.”

Cinedigm continues to focus on bringing well-established brands and film & television content from leading content owners into the growing free ad-supported television marketplace. Opportunities for premium content remain strong within the OTT ad-supported space as traditional cable and satellite services continue to lose subscribers.

About Cinedigm

For more than twenty years, Cinedigm (NASDAQ: CIDM) has led the digital transformation of the entertainment industry. Today, Cinedigm entertains hundreds of millions of consumers around the globe by providing premium content, streaming channels and technology services to the world’s largest media, technology and retail companies. For more information, visit http://www.cinedigm.com/.

Cinedigm uses, and will continue to use, its website, press releases, SEC filings, and various social media channels, including Twitter (https://twitter.com/cinedigm), LinkedIn (https://www.linkedin.com/company/cinedigm/), Facebook (https:/facebook.com/Cinedigm), StockTwits (https://stocktwits.com/CinedigmCorp) and the Company website (www.cinedigm.com) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases, SEC filings, and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases, SEC filings and on the social media channels identified above, as such information could be deemed to be material information.

Roku is a registered trademark of Roku, Inc. in the U.S. and in other countries. Trade names, trademarks and service marks of other companies appearing in this press release are the property of their respective holders.

Press Contact for CIDM:

Jill Calcaterra

[email protected]

310-466-5135

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Consumer Technology Women Entertainment Online TV and Radio Internet Film & Motion Pictures Consumer Consumer Electronics

MEDIA:

Posted on

IFIC Monthly Investment Fund Statistics – October 2020

Mutual Fund and Exchange-Traded Fund Assets and Sales

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — The Investment Funds Institute of Canada (IFIC) today announced investment fund net sales and net assets for October 2020.

Mutual fund assets totalled $1.64 trillion at the end of October 2020. Assets decreased by $24.1 billion or 1.4% compared to September 2020. Mutual funds October net sales of $3.4 billion in October 2020.

ETF assets totalled $232.1 billion at the end of October 2020. Assets decreased by $2.5 billion or 1.1% compared to September 2020. ETFs recorded net sales of $1.9 billion in October 2020.


Mutual Fund Net Sales


/Net Redemptions


($ Millions)
*

Asset Class Oct
.
2020 		Sep.
2020 		Oct
.
2019 		YTD
2020 		YTD 2019
Long-term Funds          
Balanced 1,171   (232 ) 593   (4,894 ) 81  
Equity (3 ) (1,641 ) (1,719 ) (475 ) (11,464 )
Bond 1,775   1,537   1,690   13,437   16,278  
Specialty 616   500   722   5,035   5,755  
Total Long-term Funds 3,559   165   1,285   13,104   10,650  
Total Money Market Funds (167 ) (198 ) 37   4,322   1,165  
Total 3,393   (33 ) 1,322   17,425   11,815  


Mutual Fund Net Assets ($ Billions


)
*

Asset Class Oct
. 2020 		Sep
. 2020 		Oct
. 2019 		Dec.
2019
Long-term Funds        
Balanced 812.6 825.2 805.2 821.8
Equity 522.0 534.7 514.3 532.5
Bond 238.6 237.6 215.4 218.2
Specialty 32.1 31.7 25.6 27.3
Total Long-term Funds 1,605.3 1,629.2 1,560.6 1,599.8
Total Money Market Funds 36.9 37.0 29.6 30.6
Total 1,642.1 1,666.2 1,590.2 1,630.4

* Please see below for important information regarding this data.


ETF Net Sales


/Net Redemptions


($ Millions


)
*

Asset Class Oct. 2020 Sep. 2020 Oct. 2019 YTD
2020 		YTD 2019
Long-term Funds          
Balanced 193 163   123 1,522 1,591
Equity 1,280 (343 ) 1,856 19,833 6,285
Bond 231 804   1,083 8,994 8,927
Specialty 78 52   163 1,633 756
Total Long-term Funds 1,782 675   3,225 31,982 17,558
Total Money Market Funds 154 24   621 2,385 1,791
Total 1,936 699   3,846 34,366 19,349


ETF Net Assets ($ Billions)
*

Asset Class Oct. 2020 Sep. 2020 Oct. 2019 Dec.
2019
Long-term Funds        
Balanced 6.2 6.1 4.5 4.9
Equity 138.1 140.7 117.9 126.2
Bond 75.9 76.1 62.9 65.9
Specialty 5.0 4.9 3.3 3.7
Total Long-term Funds 225.2 227.9 188.6 200.6
Total Money Market Funds 6.9 6.7 3.7 4.5
Total 232.1 234.6 192.3 205.1

* Please see below for important information regarding this data.

IFIC direct survey data (which accounts for approximately 84% of total mutual fund industry assets) is complemented by data from Investor Economics to provide comprehensive industry totals.

IFIC makes every effort to verify the accuracy, currency and completeness of the information; however, IFIC does not guarantee, warrant, represent or undertake that the information provided is correct, accurate or current.

*
Important Information Regarding Investment Fund Data
:

  1. Mutual fund data is adjusted to remove double counting arising from mutual funds that invest in other mutual funds.
  2. ETF data is not adjusted to remove double counting arising from ETFs that invest in other ETFs.
  3. The Balanced Funds category includes funds that invest directly in a mix of stocks and bonds or obtain exposure through investing in other funds.
  4. Mutual fund data reflects the investment activity of Canadian retail investors.
  5. ETF data reflects the investment activity of Canadian retail and institutional investors.

About IFIC

The Investment Funds Institute of Canada is the voice of Canada’s investment funds industry. IFIC brings together 150 organizations, including fund managers, distributors and industry service organizations, to foster a strong, stable investment sector where investors can realize their financial goals. By connecting Canada’s savers to Canada’s economy, our industry contributes significantly to Canadian economic growth and job creation. To learn more about IFIC, please visit www.ific.ca.

For more information please contact:

Pira Kumarasamy
Senior Manager, Communications and Public Affairs
[email protected]
416-309-2317



Posted on

Adlib Named Best Workplaces in Technology 2020

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — Adlib is proud to announce that we have been named to the 2020 list of Best Workplaces in Technology. Adlib received this honour after a thorough and independent analysis conducted by Great Place to Work®.

The list is based on direct feedback from employees of the hundreds of organizations that were surveyed by Great Place to Work®. The data has a 90% confidence and a plus or minus 5% margin of error.

To be eligible for this list, organizations must be Great Place to Work® – Certified in the past year and work primarily in the Technology Industry. Adlib was also awarded Great Place to Work for third consecutive year earlier this year.

“Adlib is committed to fostering an environment of collaboration, inclusivity, and support for our great team,” says Catie Sirie, VP of Business Operations. “In living our values every day, our team members come together with a common goal, demonstrating passion, purpose and a camaraderie to contribute to the growth of the organization,” she adds. “Each member of the Adlib team is highly valued and I’m proud of this great accomplishment.”

About Great Place to Work®:

Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, GPTW recognizes the world’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada.

About Adlib

Our purpose is to create intelligent data that amplifies human potential and maximizes business performance. How do we get there? Our content intelligence and automation solutions make it easy to discover, standardize, classify, extract, and leverage clean structured data from complex unstructured documents. In doing so, our global customers reduce risk, simplify compliance, automate processes, and enter a whole new level of performance. For more information, contact us at [email protected], or follow us on LinkedIn and Twitter.

Media Contact:
Marc Fuentes, Senior Director, Growth Marketing
Email: [email protected]
Phone: 905 631 2875

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a59080bb-08c1-43e6-995a-c75a71ac3d70



Posted on

Vivos Inc Applies for Breakthrough Device Designation for Radiogel™

Richland WA, Nov. 20, 2020 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that it has completed its submission to the FDA seeking Breakthrough Device Designation for Radiogel™.

This is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. It is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review, while preserving the statutory standards for premarket approval or De Novo marketing authorization.

The Breakthrough Designation process takes priority over other FDA meetings, so we elected to submit this application prior to our planned our FDA Pre-Submission meeting. We intend to schedule the pre-submission meeting in the near future, with no impact to our overall IDE submission effort. It gives us time to gather more data to share with FDA.

Dr. Mike Korenko stated, “In our opinion RadioGel™ meets the criteria for Breakthrough Device Designation, but we cannot be presumptive about the FDA determination. If granted, this designation would give RadioGel™ priority review, opening up enhanced FDA communication channels and potentially saving months in the IDE approval process.”

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

Radiogel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

Radiogel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

The Isopet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval was required for treating skin cancer, which is the largest market sector. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet® to University animal hospitals and private veterinary clinics.

Isopet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACT:

Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
[email protected]



Posted on

Brompton Funds Declare Distributions

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — (TSX:DGS.PR.A, GDV,SBC) – Brompton Funds announces distributions payable on December 14, 2020 to class A shareholders of record at the close of business on November 30, 2020 for each of the following funds:

Fund Name Ticker Amount Per Share
Global Dividend Growth Split Corp. GDV $ 0.10
Brompton Split Banc Corp. SBC $ 0.10

Brompton Funds also announces distributions payable on December 14, 2020 to preferred shareholders of record at the close of business on November 30, 2020 for the following fund:

Fund Name Ticker Amount Per Share
Dividend Growth Split Corp. DGS.PR.A $ 0.1375

The funds noted above offer distribution reinvestment plans (“DRIP”) for class A shareholders which provide class A shareholders with the ability to automatically reinvest distributions, commission free, and realize the benefits of compound growth. Class A shareholders can enroll in a DRIP program by contacting their investment advisor.

About Brompton Funds

Founded in 2000, Brompton is an experienced investment fund manager with income focused investment solutions including TSX traded closed-end funds and exchange-traded funds. For further information, please contact your investment advisor, call Brompton’s investor relations line at 416-642-6000 (toll-free at 1-866-642-6001), email [email protected] or visit our website at www.bromptongroup.com.

You will usually pay brokerage fees to your dealer if you purchase or sell
shares
of the investment fund
s
on the Toronto Stock Exchange or other alternative
Canadian trading
system
(an “exchange”). If the
shares
are purchased or sold on an exchange, investors may pay more than the current net asset value when buying
shares
of the investment fund and may receive less than the current net asset value when selling them.

There are ongoing fees and expenses associated with owning
shares
of an investment fund. An investment fund must prepare disclosure documents that contain key information about the
f
und
s
. You can find more detailed information about the
f
und
s
in the public filings available at www.sedar.com. Investment funds are not guaranteed, their values change frequently and past
performance may not be repeated.

Certain statements contained in this document constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed in this document and to other matters identified in public filings relating to the
funds
, to the future outlook of the
f
unds and anticipated events or results and may include statements regarding the future financial performance of the
funds
. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.



Posted on

Third Century Bancorp Announces Dividend

Third Century Bancorp Announces Dividend

FRANKLIN, Ind.–(BUSINESS WIRE)–
(OTCPINK: TDCB) – Third Century Bancorp, an Indiana corporation and parent company of Mutual Savings Bank, announced today that on November 19, 2020, the Board of Directors declared a dividend of $0.08 per share for shareholders of record on December 15, 2020. The dividend payable date is January 4, 2021.

Founded in 1890, Mutual Savings Bank is a full-service financial institution with over $202 million in assets as of September 30, 2020. In addition to its main office at 80 East Jefferson Street, Franklin, Indiana, the bank operates branches in Franklin at 1124 North Main Street, and in the Otterbein Franklin SeniorLife Community, as well as in Nineveh, Trafalgar, and Greenwood, Indiana.

David A. Coffey, President and Chief Executive Officer

Ryan W. Cook, Senior Vice President and Chief Financial Officer

Tel. 317-736-7151 Fax 317-736-1726

KEYWORDS: Indiana United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

FoxGuard Solutions Teams Up with Industrial Defender – Transforming Patch and Vulnerability Management for OT Security Teams.

This partnership combines Industrial Defender’s depth and breadth of asset data collection with FoxGuard’s ability to report, acquire, validate and deploy vendor-approved patch and vulnerability information.

Christiansburg, VA, Nov. 20, 2020 (GLOBE NEWSWIRE) — Industrial Defender and FoxGuard Solutions®, two operational technology (OT) security pioneers, announced a new partnership today that will transform patch and vulnerability management for critical infrastructure companies. Keeping up with emerging critical vulnerabilities in industrial control systems (ICS) is a major challenge. With this joint solution, security teams can make smarter patching decisions with simple visualizations of which assets are missing vendor-approved patches or have open vulnerabilities in one place. 

“The partnership between FoxGuard Solutions and Industrial Defender will simplify and enhance cybersecurity efforts required within ICS environments,” says Michael Trautman, CTO & VP Cybersecurity at FoxGuard Solutions. “Aligning patch and vulnerability intelligence data with asset information and process driven tools results in a robust solution providing process efficiencies within security teams serving critical infrastructure markets.”

“Our collaboration with FoxGuard Solutions is going to revolutionize patch and vulnerability management for ICS environments,” says Jim Crowley, CEO at Industrial Defender. “We are taking what was once a complex, manual task and simplifying it so that OT security teams can make timely, informed decisions about emerging threats.”

For a complete overview of the benefits of this integration and how it works, read the joint solution brief here: https://foxguardsolutions.com/wp-content/uploads/2020/07/SB_FoxGuard_111820.pdf

About FoxGuard Solutions
FoxGuard Solutions opened in 1981 and develops custom cybersecurity, compliance and industrial computing solutions. FoxGuard provides reliable, secure and configurable patch management reporting services, which include availability reporting and applicability analysis for information technology (IT) and operational technology (OT) assets used in critical infrastructure environments. 
Visit www.foxguardsolutions.com to learn more.
FoxGuard Solutions is a wholly owned subsidiary of Framatome, an international leader in nuclear energy.

Media Contact:
Marcie Killen
FoxGuard Solutions
Senior Marketing Operations Manager
[email protected]

REQUEST YOUR DEMO

About Industrial Defender

Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com.

Media Contact:
Erin Anderson
Industrial Defender
Director of Marketing
[email protected]

Attachment



Posted on

NXTC CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against NextCure Inc.

PR Newswire

NEW YORK, Nov. 20, 2020 /PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that: (i)  purchased or acquired the securities of NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) securities between November 5, 2019 to July 14, 2020; and  (ii) purchased or acquired NextCure common stock pursuant to or traceable to the Company’s Registration Statement on Form S-1 which was filed with and declared effective by the SEC on November 12, and November 14, 2019. The lawsuit filed in the United States District Court for the Southern District of New York alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.

If you purchased NextCure securities, and/or would like to discuss your legal rights and options please visit NXTC Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Throughout the Class Period, Defendants misled investors regarding its leading treatment candidate, NC318, which was a first-in-class immunomedicine targeting a novel immunomodulatory receptor, called Siglec-15, or S15, particularly in patients with advanced or metastatic solid tumors.

On July 13, 2020, NextCure made a shocking admission.  Specifically, in a press release entitled, “NextCure provides an Interim update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure Chief Medical Officer,” NextCure announced that the Company was no longer planning to “advance the nonsmall cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial,” citing “clinical response data” and “current enrollment criteria.” The July 13, 2020 announcement continued, stating, in relevant part, “The analysis of biomarker data for these cohorts has been delayed and is not yet complete.  The company will evaluate whether to pursue additional monotherapy studies in NSCLC and ovarian cancer after a review of that information.”

On this news, NextCure’s shares, which had closed at $17.88 per share on July 10, 2020, dropped over 54% the next trading day to close at $8.15 per share on July 13, 2020 on unusually high trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased NextCure securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/nextcureinc-nxtc-shareholder-class-action-lawsuit-stock-fraud-313/apply/ contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected] .

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nxtc-class-action-deadline-bernstein-liebhard-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-nextcure-inc-301177836.html

SOURCE Bernstein Liebhard LLP

Posted on

mdf commerce announces closing of the acquisition of Vendor Registry

MONTREAL, Nov. 20, 2020 (GLOBE NEWSWIRE) — mdf commerce inc. (“mdf commerce”) (TSX:MDF), a leader in SaaS commerce technology solutions, is pleased to announce the closing of the transaction previously announced on November 2, 2020 regarding the acquisition of Vendor Registry, Inc.

About mdf commerce inc.

mdf commerce inc. (TSX:MDF), formerly known as Mediagrif Interactive Technologies Inc., enables the flow of commerce by providing a broad set of SaaS solutions that optimize and accelerate commercial interactions between buyers and sellers. Our platforms and services empower businesses around the world, allowing them to generate billions of dollars in transactions on an annual basis. Our strategic sourcing, unified commerce and emarketplace platforms are supported by a strong and dedicated team of more than 600 employees based in Canada, the United States, Denmark, Ukraine and China. For more information, please visit us at mdfcommerce.com, follow us on LinkedIn or call at 1877-677-9088.

About
Vendor Registry,
Inc.

Based in Knoxville, Tennessee, Vendor Registry serves over 400 public agencies and over 70,000 vendors across the United States. Vendor Registry’s mission is to streamline the purchasing process for cities, counties, utilities, higher education and school boards in order to generate new revenues for vendors and suppliers, decrease costs for government and institutional purchasing departments and save valuable time for all parties involved.

For further information:

mdf commerce
i
nc.

André Leblanc
Vice President, Marketing and Public Affairs
Tel.: 450 449-0102, ext: 8220
Mobile: 514-961-0882
Email: [email protected]



Posted on

RPh on the Go Helps Fill Hundreds of Critical Pharmacy Roles in Response to COVID Pandemic

With the news of a COVID vaccine on the horizon, pharmacies will need extra support to meet inoculation demands for patients seeking both the flu and COVID vaccines

CHICAGO, Ill., Nov. 20, 2020 (GLOBE NEWSWIRE) — For the nation’s pharmacies, this year’s flu season poses unique challenges as it coincides with a rise in COVID cases and the pending COVID-19 vaccine rollout. With likely unprecedented numbers of patients flocking to pharmacies seeking both the flu and COVID-19 vaccines, facilities are in planning overdrive to create staffing plans to meet patient demands.

 

One leading pharmacy staffing agency, RPh on the Go, is putting its expertise to use to help pharmacies prepare for the influx of patients by ensuring they have the staff necessary to continue to deliver high-quality care and exceptional customer service.

 

With more than 40 years of experience in the pharmacy staffing sector, RPh on the Go boasts a nationwide network of pharmacy professionals that includes pharmacists, pharmacy technicians and pharmacy management. The firm leverages its deep expertise in the industry and its vast pool of professionals to match pharmacies with the most qualified talent that meets their unique needs.

 

With its current focus on supporting pharmacies during the pandemic and flu season, RPh on the Go will be partnering with pharmacies across the country by staffing them with pharmacists who are prepared to administer vaccines, dispense medication and administer COVID-19 tests. RPh on the Go leadership hopes to help mitigate the spread of COVID across the country in partnership with nationwide pharmacies.

 

“Pharmacies are struggling to fill unexpected absences and are overwhelmed trying to devise plans to augment staff to meet a nationwide spike in demand for pharmacists and pharmacy technicians,” said Luis Balaguer, Vice President at RPh on the Go. “We are equipped to help during this critical moment in the pandemic by relieving the pressure on pharmacies to find essential workers during this crisis.”

 

Throughout the COVID-19 pandemic, RPh on the Go has deployed pharmacy professionals to retail, federal and hospital pharmacies to provide relief to workers on the frontlines. The group has also partnered with many pharmacies on contingency plans to ensure they are prepared should they become overwhelmed due to a COVID-19 spike in their region.

 

To learn more about RPh on the Go, visit http://rphonthego.com.

 

About RPh on the Go

RPh on the Go is a highly experienced pharmacy staffing company located in Chicago, IL. The company identifies and recruits exceptional pharmacy professionals and connects them with retail, hospital and federal pharmacies nationwide, typically on a temporary basis. Visit https://rphonthego.com to learn more.

# # #

 

For more information about RPh on the Go or for media inquiries, please contact Tera Rowland at 904.360.2630 or [email protected].



Tera Rowland
RPh on the Go
904.360.2630
[email protected]